Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2008

View Archived Issues

AstraZeneca reports full year 2007 R&D highlights

GeoVax Clade B DNA/MVA HIV/AIDS vaccine to proceed to phase II

VICTOR-E1 data show sustained viral suppression with vicriviroc in HIV patients

FDA grants approval to Diamyd to initiate phase I trial of NP-2 for chronic pain

Raltegravir efficacy maintained through 48 weeks in BENCHMRK studies

Icagen announces completion of investment by Pfizer

NRDL and Lilly sign drug development agreement spanning multiple therapeutic areas

AnGes reports results from phase II clinical trials of ointment for atopic dermatitis

New therapeutic agents for cardiovascular disorders reported in recent patent literature

Novel immunomodulators disclosed in recent patents

Low-dose arm continues to be tested in phase III MDP 301 trial of Indevus' PRO-2000

EMEA recommends that new warnings be included in product information for Novartis' Sebivo

Can-Fite doses first cohort of patients in phase I CF-102 trial

FDA grants fast track status to levodopa/carbidopa intestinal gel

LAT-967 shows potential for AD by inducing Sp1 degradation

Takeda discontinues matuzumab development

Agonist-induced CCR5 internalization, an alternative mechanism to prevent HIV infection

Lundbeck initiates enrollment in phase II clinical study of Lu-AA-34893 for bipolar disorder

Recent patents describe novel compounds for the treatment of cancer

Activation of osteoblast GPCRs potentially useful as bone repair therapy

FDA approves Xyzal oral solution for the relief of allergies and urticaria

Newron completes enrollment in phase II study of ralfinamide in post-op dental pain

Bayer and Onyx terminate clinical phase III Nexavar study in NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.